Published in Antimicrob Agents Chemother on November 01, 1999
Peptidoglycan crosslinking relaxation promotes Helicobacter pylori's helical shape and stomach colonization. Cell (2010) 2.02
Role of AmiA in the morphological transition of Helicobacter pylori and in immune escape. PLoS Pathog (2006) 1.34
Development of inducible systems to engineer conditional mutants of essential genes of Helicobacter pylori. Appl Environ Microbiol (2008) 1.21
Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev (2014) 1.17
Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.12
Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.07
Effect of host species on recG phenotypes in Helicobacter pylori and Escherichia coli. J Bacteriol (2004) 0.97
Dynamic localization of MreB in Vibrio parahaemolyticus and in the ectopic host bacterium Escherichia coli. Appl Environ Microbiol (2008) 0.92
Urease activity and urea gene sequencing of coccoid forms of H. pylori induced by different factors. Curr Microbiol (2008) 0.85
A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity. PLoS One (2014) 0.84
Contribution of specific amino acid changes in penicillin binding protein 1 to amoxicillin resistance in clinical Helicobacter pylori isolates. Antimicrob Agents Chemother (2010) 0.83
A microtiter plate-based beta-lactam binding assay for inhibitors of high-molecular-mass penicillin-binding proteins. Anal Biochem (2009) 0.82
Mutations to essential orphan response regulator HP1043 of Helicobacter pylori result in growth-stage regulatory defects. Infect Immun (2013) 0.82
Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy. Antimicrob Agents Chemother (2015) 0.76
Ultrastructural Changes in Clinical and Microbiota Isolates of Klebsiella pneumoniae Carriers of Genes bla SHV, bla TEM, bla CTX-M, or bla KPC When Subject to β-Lactam Antibiotics. ScientificWorldJournal (2015) 0.75
Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology. Sci Rep (2015) 0.75
Analysis of aztreonam-inducing proteome changes in nondividing filamentous Helicobacter pylori. Curr Microbiol (2012) 0.75
The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 34.00
Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12. Proc Natl Acad Sci U S A (1975) 18.13
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol Rev (1974) 7.49
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother (1984) 3.35
Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother (1979) 3.27
Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology. Antimicrob Agents Chemother (1979) 2.89
Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother (1995) 2.48
Use of autoradiography to assess viability of Helicobacter pylori in water. Appl Environ Microbiol (1993) 2.16
Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun (1997) 1.96
Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. Adv Intern Med (1996) 1.96
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Coccoid Helicobacter pylori not culturable in vitro reverts in mice. Microbiol Immunol (1994) 1.79
Coccoid and spiral Helicobacter pylori differ in their abilities to adhere to gastric epithelial cells and induce interleukin-8 secretion. Infect Immun (1997) 1.71
Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli. J Bacteriol (1996) 1.57
Helicobacter pylori: a fickle germ. Microbiol Immunol (1994) 1.47
Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid form. Infect Immun (1996) 1.47
Coccoid forms of Helicobacter pylori in the human stomach. Am J Clin Pathol (1994) 1.47
Virulence of coccoid and bacillary forms of Helicobacter pylori in gnotobiotic piglets. J Infect Dis (1995) 1.44
Coccoid like forms (CLF) of Helicobacter pylori. Enzyme activity and antigenicity. Zentralbl Bakteriol (1993) 1.38
Penicillin-binding proteins and bacterial resistance to beta-lactams. Antimicrob Agents Chemother (1993) 1.37
Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study. J Med Microbiol (1987) 1.35
A new, highly sensitive method for the detection and quantification of penicillin-binding proteins. Biochem J (1993) 1.32
Use of biotinylated beta-lactams and chemiluminescence for study and purification of penicillin-binding proteins in bacteria. Antimicrob Agents Chemother (1994) 1.29
Morphologic conversion of Helicobacter pylori from bacillary to coccoid form. Eur J Clin Microbiol Infect Dis (1996) 1.29
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.24
In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori. Antimicrob Agents Chemother (1989) 1.23
Electron microscopic study of association between coccoid forms of Helicobacter pylori and gastric epithelial cells. Am J Gastroenterol (1995) 1.13
In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother (1994) 1.08
Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.06
Target for bacteriostatic and bactericidal activities of beta-lactam antibiotics against Escherichia coli resides in different penicillin-binding proteins. Antimicrob Agents Chemother (1995) 1.05
Is the coccoid form of Helicobacter pylori viable? Microbios (1996) 1.05
The pathogenic role of the coccoid form of Helicobacter pylori. Cytobios (1995) 0.98
Infection of BALB/c A mice by spiral and coccoid forms of Helicobacter pylori. J Med Microbiol (1997) 0.97
Diversity in protein synthesis and viability of Helicobacter pylori coccoid forms in response to various stimuli. Infect Immun (1998) 0.95
Growth and morphological transformations of Helicobacter pylori in broth media. J Clin Microbiol (1997) 0.95
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Antimicrob Agents Chemother (1997) 0.90
Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins. Antimicrob Agents Chemother (1990) 0.86
Helicobacter pylori and gastrointestinal disease. J Clin Pharmacol (1995) 0.85
Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori. J Chemother (1996) 0.80
Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. Rev Infect Dis (1980) 3.70
Catabolism of glucose and fatty acids by virulent Treponema pallidum. Infect Immun (1977) 2.07
ALGINATE LYASE: review of major sources and enzyme characteristics, structure-function analysis, biological roles, and applications. Annu Rev Microbiol (2000) 1.98
Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 1.45
Release of interleukin-8, interleukin-6, and colony-stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol (1993) 1.38
Alginate synthesis in Pseudomonas aeruginosa: the role of AlgL (alginate lyase) and AlgX. J Bacteriol (1996) 1.32
Serum sensitivity of a Pseudomonas aeruginosa mucoid strain. Infect Immun (1984) 1.21
Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1986) 1.20
Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.12
Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens. J Clin Microbiol (1984) 1.05
Effects of Pseudomonas aeruginosa rhamnolipids on human monocyte-derived macrophages. J Leukoc Biol (1992) 1.05
Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect Immun (1992) 1.05
The serum sensitivity, colonial morphology, serogroup specificity, and outer membrane protein of Pseudomonas aeruginosa strains isolated from several clinical sites. Diagn Microbiol Infect Dis (1983) 1.04
Inhibition of macrophage phagocytosis by Pseudomonas aeruginosa rhamnolipids in vitro and in vivo. Curr Microbiol (1996) 1.03
Vitamin B6 requirements of nutritionally variant Streptococcus mitior. J Clin Microbiol (1982) 0.98
The role of natural IgG and complement in the phagocytosis of type 4 Neisseria gonorrhoeae by human polymorphonuclear leukocytes. J Infect Dis (1979) 0.89
Addition of a bacterial alginate lyase to purulent CF sputum in vitro can result in the disruption of alginate and modification of sputum viscoelasticity. Pulm Pharmacol (1994) 0.87
Gonococci-human polymorphonuclear leukocyte interactions: metabolic studies associated with attachment and ingestion. Infect Immun (1980) 0.85
Analysis and expression of algL, which encodes alginate lyase in Pseudomonas syringae Pv. syringae. DNA Seq (2001) 0.83
Characterization of alginate lyase from Pseudomonas syringae pv. syringae. J Bacteriol (2000) 0.82
Pseudomonas-infected cystic fibrosis patient sputum inhibits the bactericidal activity of normal human serum. Pediatr Res (1983) 0.81
Cellular responses and proteomic analysis of Escherichia coli exposed to green tea polyphenols. Curr Microbiol (2007) 0.81
Malathion and phenthoate carboxylesterase activities in pulmonary alveolar macrophages as indicators of lung injury. Toxicol Appl Pharmacol (1983) 0.76
2,3-butanedione, an electron-stabilizing compound, as a modifier of sensitivy of Bacillus megaterium spores to X-rays. Int J Radiat Biol Relat Stud Phys Chem Med (1968) 0.75